Search Results - "Yelle, L."

Prognosis in young women less than 40 years of age with brain metastasis from breast cancer by Mustillo, A, Ayoub, J P, Charpentier, D, Yelle, L, Florescu, M

“…Brain metastasis from breast cancer (bca) in young women is doubly devastating because both quality of life and life expectancy are significantly reduced. With…”
Get full text

A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada by Beauchemin, C, Letarte, N, Mathurin, K, Yelle, L, Lachaine, J

“…Objective Considering the increasing number of treatment options for metastatic breast cancer (MBC), it is important to develop high-quality methods to assess…”
Get more information

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG) by Trudeau, M.E., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L., Matthews, S., Eisenhauer, E.

“…Temozolomide is an oral alkylating agent that crosses the blood–brain barrier, and has preclinical activity in breast cancer. This phase II trial sought to…”
Get full text

PCN33 Progression-Free Survival as a Surrogate for Overall Survival in Metastatic Breast Cancer by Beauchemin, C, Cooper, D, Lapierre, M.E, Yelle, L, Lachaine, J

Get full text

P142 Rechallenge of patients previously treated with adjuvant anthracyclines using pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C)as first-line chemotherapy for metastaticbreast cancer (MBC) by Trudeau, M, Clemons, M, Provencher, L, Panasci, L, Yelle, L, Rayson, D, Latreille, J, Vandenberg, T, Pouliot, J

Get full text

A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada by Beauchemin, C, Letarte, N, Mathurin, K, Yelle, L, Lachaine, J

Get full text

PCN99 - A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada by Beauchemin, C, Letarte, N, Mathurin, K, Yelle, L, Lachaine, J

Get full text

PRM2 - How To Conduct Economic Evaluations Of New Treatments For Advanced Cancer When Overall Survival Data Are Not Available? Results From A Systematic Literature Review by Beauchemin, C, Lapierre, M, Letarte, N, Yelle, L, Lachaine, J

Get full text

How To Conduct Economic Evaluations Of New Treatments For Advanced Cancer When Overall Survival Data Are Not Available? Results From A Systematic Literature Review by Beauchemin, C, Lapierre, M, Letarte, N, Yelle, L, Lachaine, J

Get full text

Progression-Free Survival as a Surrogate for Overall Survival in Metastatic Breast Cancer by Beauchemin, C., Cooper, D., Lapierre, M., Yelle, L., Lachaine, J.

Get full text

Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial by Yelle, L, Bergsagel, D, Basco, V, Brown, T, Bush, R, Gillies, J, Israels, L, Miller, A, Rideout, D, Whitelaw, D

“…The purpose of this study was to compare four methods of treatment for stage III-IV Hodgkin's disease. Between January 1972 and September 1976, 266 patients…”
Get more information

Abstract P3-15-09: Impact of granulocyte colony-stimulating factors on febrile neutropenia risk during early-stage breast cancer treatment by Ben Abdallah, SS, Letarte, N, Messier, C, Charpentier, D, Yelle, L, Younan, R, Bestawros, A

“…Febrile neutropenia (FN) is a significant cause of both mortality and morbidity in patients undergoing adjuvant or neoadjuvant chemotherapy for early-stage…”
Get full text

Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301 by Kaufman, PA, Yelle, L, Cortes, J, Perez, EA, Awada, A, Wanders, J, Olivo, MS, He, Y, Dutcus, CE, Twelves, C

“…Background: The Phase III trial (NCT00337103) compared eribulin (E) with capecitabine (C) in patients (pts) with metastatic breast cancer (MBC) in the 1st-,…”
Get full text

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group by Latreille, J, Pater, J, Johnston, D, Laberge, F, Stewart, D, Rusthoven, J, Hoskins, P, Findlay, B, McMurtrie, E, Yelle, L, Williams, C, Walde, D, Ernst, S, Dhaliwal, H, Warr, D, Shepherd, F, Mee, D, Nishimura, L, Osoba, D, Zee, B

“…To evaluate the roles of granisetron and dexamethasone for emesis control on days 2 through 7 after the administration of cisplatin in doses of 50 mg/m2 or…”
Get more information

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes by Kaufman, PA, Awada, A, Twelves, C, Yelle, L, Perez, EA, Wanders, J, Olivo, MS, He, Y, Dutcus, CE

“…Background: Eribulin is a non-taxane microtubule dynamics inhibitor. In a previous Phase III trial, eribulin demonstrated a statistically significant…”
Get full text

Abstract P3-13-03: A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival by Awada, A, Kaufman, PA, Yelle, L, Cortes, J, Wanders, J, O'Shaughnessy, J, Olivo, MS, He, Y, Garzon, F, Dutcus, CE, Binder, TA, Twelves, C, Perez, EA

“…Background A Phase III trial (Study 301; NCT00337103) in MBC comparing eribulin (E) with capecitabine (C) showed a trend for improved overall survival (OS)…”
Get full text

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer by CHAN, S, FRIEDRICHS, K, YELLE, L, VON MINCKWITZ, G, KOREC, S, SIMMONDS, P, BUZZI, F, MANCHA, R. G, RICHARDSON, G, WALPOLE, E, RONZONI, M, MURAWSKY, M, NOEL, D, ALAKL, M, RIVA, A, CROWN, J, PINTER, T, VAN BELLE, S, VOROBIOF, D, DUARTE, R, GIL, M. G, BODROGI, I, MURRAY, E

“…This phase III study compared docetaxel and doxorubicin in patients with metastatic breast cancer who had received previous alkylating agent-containing…”
Get full text

The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer by Jolivet, J, Bélanger, K, Yelle, L, Guévin, R, Potvin, M, Wilson, J, Rudinskas, L, Latreille, J, Dionne, J, Gagné, L

“…We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer. 8 patients received mitoxantrone 10…”
Get more information

Influence of ethanol on hepatic glutathione content and on the activity of glutathione S-transferases and epoxide hydrase in the rat by Hétu, C, Yelle, L, Joly, J G

“…Chronic ethanol administration to female rats for 3 weeks was associated with a 60% increase in liver microsomal cytochrome P-450 content. This effect was…”
Get more information

Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as 1 st -line chemotherapy for metastatic breast cancer (MBC) patients previously treated with adjuvant anthracyclines by Vandenberg, T. A., Trudeau, M., Provencher, L., Panasci, L. C., Yelle, L., Rayson, D., Latreille, J., Clemons, M., Giroux, M., Pouliot, J.

“…Abstract only 10627 Background: Anthracyclines (A) are key elements in adjuvant and metastatic chemotherapy regimens for breast cancer. Pre-exposure limits the…”
Get full text